BDX · Becton, Dickinson and Company
$154.512026-05-17Sector: Healthcare; Industry: Medical - Instruments & Supplies; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$56
-63.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($56 · $56) Analysts Range ($170 · $215) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2022.Q1 | $19.1B | — | 12.9% | 0.7% | $2.5B | $84MM | $2.5B | 3.2% | — | 5.7% | $43.4B | $7.34 | — |
| 2023.Q1 | $18.9B | -1.4% | 13.3% | 5.3% | $2.4B | −$2.5B | −$83MM | 5.4% | — | 5.4% | $45.0B | $6.24 | — |
| 2024.Q1 | $19.4B | 2.7% | 12.0% | 15.3% | $2.0B | $1.8B | $3.7B | 5.2% | — | 4.4% | $43.9B | $5.21 | — |
| 2025.Q1 | $20.2B | 4.2% | 13.1% | 11.6% | $2.3B | −$3.4B | −$1.1B | 6.2% | — | 5.1% | $46.7B | $5.98 | — |
| 2026.Q1 | $21.9B | 8.6% | 13.6% | 14.8% | $2.5B | $603MM | $3.1B | 5.6% | — | 5.4% | $47.5B | $6.16 | 14.7 |
| italics below = DCF projection · 10yr Rev CAGR: 2.1% |
| 2027.Q1 | $19.3B | +-11.8% | 13.0% | 15.3% | $2.1B | $0MM | $2.1B | 7.3% | $2.0B | 4.5% | $47.5B | $6.77 | 22.8 |
| 2028.Q1 | $19.8B | +2.5% | 13.8% | 15.9% | $2.3B | −$1.1B | $1.2B | 7.5% | $1.0B | 4.8% | $48.6B | $7.35 | 21.0 |
| 2029.Q1 | $20.5B | +3.6% | 13.8% | 16.4% | $2.4B | −$1.6B | $718MM | 7.6% | $578MM | 4.8% | $50.3B | $7.55 | 20.5 |
| 2030.Q1 | $21.3B | +3.7% | 14.4% | 16.9% | $2.6B | −$1.8B | $722MM | 7.7% | $540MM | 5.0% | $52.1B | $8.15 | 19.0 |
| 2031.Q1 | $22.1B | +3.8% | 14.4% | 17.4% | $2.6B | −$2.0B | $655MM | 7.8% | $454MM | 5.0% | $54.1B | $8.40 | 18.4 |
|
| Term. Yr+ | $28.0B | 4.1% | 19.5% | 20.0% | $4.4B | −$2.1B | $2.3B | 8.6% | $23.8B | 8.6% | — | — | — |
Active scenario IV: $56 (-63.7% vs market)